Form 4: Boundless Bio Director, Jennifer Lew, Reports Stock Option Grant
SEC Form 4 Filing
Director Jennifer Lew reports acquisition of stock options in Boundless Bio, Inc.
Summary
- On March 27, 2024, Jennifer Lew, a director of Boundless Bio, Inc., reported the acquisition of 13,219 stock options.
- The options have an exercise price of $0.
- The stock options vest in 36 substantially equal monthly installments beginning on April 27, 2024.
- The options expire on March 26, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the sentiment is neutral.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Stakeholder Impact
- The stock option grant could incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: acquisition of stock options. |
| 04/27/2024 | Vesting start date for the stock options. |
| 03/26/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.